Also, it has been shown that the lower dose of erlotinib (100 mg/d (per day) or 254 μmol/d) achieved comparable efficacy compared with the standard dose of gefitinib (250 mg/d or 559 μmol/d) in EGFR-mutated NSCLC [97]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.